Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Inoges, S. (Susana) | |
dc.creator | Rodriguez-Calvillo, M. (Mercedes) | |
dc.creator | Zabalegui, N. (Natalia) | |
dc.creator | Lopez-Diaz-de-Cerio, A. (Ascensión) | |
dc.creator | Villanueva, H. (Helena) | |
dc.creator | Soria, E. (Elena) | |
dc.creator | Suarez, L. (Lilia) | |
dc.creator | Rodriguez-Caballero, A. (Arancha) | |
dc.creator | Pastor, F. (Fernando) | |
dc.creator | Garcia-Muñoz, R. (R.) | |
dc.creator | Panizo, C. (Carlos) | |
dc.creator | Perez-Calvo, J. (Javier) | |
dc.creator | Melero, I. (Ignacio) | |
dc.creator | Rocha, E. (Eduardo) | |
dc.creator | Orfao, A. (Alberto) | |
dc.creator | Bendandi, M. (Maurizio) | |
dc.date.accessioned | 2011-07-04T11:50:56Z | - |
dc.date.available | 2011-07-04T11:50:56Z | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Inoges S, Rodriguez-Calvillo M, Zabalegui N, Lopez-Diaz de Cerio A, Villanueva H, Soria E, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006 Sep 20;98(18):1292-1301. | es_ES |
dc.identifier.issn | 1460-2105 | - |
dc.identifier.uri | https://hdl.handle.net/10171/18723 | - |
dc.description.abstract | BACKGROUND: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. A patient's second complete response is typically shorter than that patient's first complete response. Idiotype vaccines can elicit specific immune responses and molecular remissions in patients with follicular lymphoma. However, a clinical benefit has never been formally proven. METHODS: Thirty-three consecutive follicular lymphoma patients in first relapse received six monthly cycles of CHOP-like chemotherapy. Patients who achieved a second complete response were vaccinated periodically for more than 2 years with autologous lymphoma-derived idiotype protein vaccine. Specific humoral and cellular responses were assessed, and patients were followed for disease recurrence. Statistical tests were two-sided. RESULTS: Idiotype vaccine could be produced for 25 patients who had a second complete response. In 20 patients (80%), a humoral (13/20) and/or a cellular (18/20) idiotype-specific response was detected. The median duration of the second complete response has not been reached, but it exceeds 33 months (range = 20+ to 51+ months). None of the 20 responders relapsed while undergoing active vaccination. All responders with enough follow-up for the comparison to be made experienced a second complete response that was statistically significantly (P<.0001) longer than both their first complete response (18 of 18 patients) and than the median duration of a CHOP-induced second complete response, i.e., 13 months (20 of 20 patients). The five nonresponders all had a second complete response that was shorter (median = 10 months; range = 8-13 months) than their first complete response (median = 17 months; range = 10-39 months). CONCLUSIONS: Idiotypic vaccination induced a specific immune response in the majority of patients with follicular lymphoma. Specific immune response was associated with a dramatic and highly statistically significant increase in disease-free survival. This is the first formal demonstration of clinical benefit associated with the use of a human cancer vaccine. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Cancer Vaccines/immunology | es_ES |
dc.subject | Lymphoma, Follicular/drug therapy | es_ES |
dc.subject | Lymphoma, Follicular/immunology | es_ES |
dc.subject | Immunoglobulin Idiotypes/therapeutic use | es_ES |
dc.title | Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://jnci.oxfordjournals.org/content/98/18/1292 | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.